RBC Capital Maintains Outperform on Pharvaris, Raises Price Target to $52
RBC Capital analyst Brian Abrahams maintains Pharvaris (NASDAQ:PHVS) with a Outperform and raises the price target from $51 to $52.
Stocks · News reference
Pharvaris Says FDA Accepts NDA For Deucrictibant IR Capsule (20 Mg) For On-Demand Treatment Of Hereditary Angioedema Attacks; PDUFA Target Action Date Set April 23, 2027
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Guggenheim Maintains Buy on Pharvaris, Raises Price Target to $40
Guggenheim analyst Debjit Chattopadhyay maintains Pharvaris (NASDAQ:PHVS) with a Buy and raises the price target from $39 to $40.
Citizens Maintains Market Outperform on Pharvaris, Raises Price Target to $75
Citizens analyst Jonathan Wolleben maintains Pharvaris (NASDAQ:PHVS) with a Market Outperform and raises the price target from $74 to $75.
Pharvaris Q2 EPS $(0.81) Misses $(0.74) Estimate
Pharvaris (NASDAQ:PHVS) reported quarterly losses of $(0.81) per share which missed the analyst consensus estimate of $(0.74) by 9.46 percent. This is a 13.83 percent increase over losses of $(0.94) per share from the